Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/14/19 | Quarterly report pursuant to Section 13 or 15(d) |
|
 |
45 | |
| 11/14/18 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
52 | |
| 08/13/18 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
60 | |
| 05/14/18 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
50 | |
| 11/14/17 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
60 | |
| 08/14/17 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
52 | |
| 05/15/17 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
51 | |
| 11/14/16 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
60 | |
| 08/15/16 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
67 | |
| 05/13/16 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
47 |